Paper Details

  1. Home
  2. Paper Details

A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.

Author: BaumgartnerKaren E, ChamberlainMarc C, ColmanHoward, ConradCharles A, FormanArthur D, GilbertMark R, GlantzMichael J, GrovesMorris D, HessKenneth R, HsuSigmund, HunterKathy U, IctechSandra, PuduvalliVinay K, WefelJeffrey S, YungW K Alfred

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Intraventricular topotecan, a chemotherapy drug delivered directly to the brain, is well-tolerated but does not significantly improve survival in patients with neoplastic meningitis, a type of cancer that affects the brain and spinal cord. While topotecan is safe, it may not be the most effective treatment option for this type of cancer.
Paper Details　
Original Abstract of the Article :
To determine the therapeutic efficacy (13-week and 26-week CNS progression-free survival [PFS], response rate, and overall survival) and safety of intraventricular (IVent) topotecan in patients with neoplastic meningitis (NM), we conducted a phase II, open-label, nonrandomized, single-arm trial of I...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613823/

データ提供：米国国立医学図書館（NLM）

Intrathecal Topotecan: A New Treatment for Meningeal Malignancies

Meningeal malignancies, cancers that affect the membranes surrounding the brain and spinal cord, pose a significant challenge for medical professionals. This study investigates the efficacy and safety of intrathecal topotecan, a chemotherapy drug administered directly into the cerebrospinal fluid, in treating patients with meningeal malignancies. The researchers aim to determine the effectiveness of this treatment in controlling disease progression and improving survival.

Exploring New Treatment Options: Intrathecal Topotecan for Meningeal Malignancies

The study found that intrathecal topotecan was well tolerated but provided no significant improvement in survival compared to other intrathecal therapies. The researchers suggest that combining topotecan with other treatments may offer a more effective approach.

Navigating the Desert of Cancer: Finding New Paths to Treatment

Imagine a patient facing the daunting challenge of meningeal malignancies, seeking hope and effective treatment options. This study explores the complex landscape of cancer treatment, shedding light on the potential of intrathecal topotecan and the need for further research into combination therapies.

Dr.Camel's Conclusion

This research provides valuable insights into the potential of intrathecal topotecan for treating meningeal malignancies, highlighting the importance of ongoing research and development of novel treatment strategies for this challenging condition. It's like navigating the vast and often treacherous desert of cancer research, seeking new paths to better treatments and improved outcomes for patients.

Date :
  1. Date Completed 2008-06-10
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

18316473

DOI: Digital Object Identifier

PMC2613823

Related Literature

Article Analysis
・Side Effects of topotecan injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.